Skip to main content

Table 6 Major adverse events in study subjects with SLE

From: Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: A case-control study

Adverse events*

IVCY group

Steroid group

 

n = 29

n = 33

Amenorrhea

17 (59%)

9 (27%)

Elevation of liver enzymes

2 (7%)

0 (0%)

Hematological disorder

1 (3%)

0 (0%)

Herpes Zoster infection

1 (3%)

2 (6%)

Cytomegalovirus infection

0 (0%)

1 (3%)

Tinea corporis

0 (0%)

1 (3%)

Myocarditis

1 (3%)

0 (0%)

  1. *Adverse events that are usually not regarded as IVCY-related are excluded from this table.
  2. IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus.